There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]
For best results, apply after your Perricone MD serum, serum concentrate or facial cream
Outcome misclassification : patients may label vulvar skin laxity, pelvic floor weakness, bleeding changes, and libido/arousal effects under the umbrella of vaginal changes, requiring clearer phenotyping
This helps dilute bacteria and reduce symptoms
Better blood flow: Weight loss improves cardiovascular health and blood circulation, which directly affects erectile function and arousal for both sexes